Lumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%

MT Newswires Live

07/21

Lumos Diagnostics (ASX:LDX) is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.

The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.

FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.

Shares fell 3% in midday trade Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2653223240"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653223240\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653223240?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653223240","market":"nz","top_or_hot":-1,"title":"Lumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX) is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.</p><p>The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.</p><p>FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.</p><p>Shares fell 3% in midday trade Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-21 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX) is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.</p><p>The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.</p><p>FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.</p><p>Shares fell 3% in midday trade Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LDX.AU","symbol_name":"LUMOS DIAGNOSTICS HOLDINGS L","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653223240","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653223240","pubTimestamp":1784601347,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics  is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.Shares fell 3% in midday trade Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK7126":"医疗保健用品"},"translate_title":"Lumos Diagnostics 推进美国快速检测商业化；股价下跌 3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1},"content_text":"Lumos Diagnostics (ASX:LDX) is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.Shares fell 3% in midday trade Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}